

INFORMATION DISCLOSURE CITATION <i>(Use several sheets if necessary)</i>		ATTY. DOCKET NO. PC10228A	SERIAL NO. 09/443,542
		APPLICANT Farzan Rastinejad et al.	
		FILING DATE November 19, 1999	GROUP 1614

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

## FOREIGN PATENT DOCUMENTS

PATENT & TRADEMARK OFFICE	AUG 14 2000	SC141	DOCUMENT NUMBER				DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
			YES	NO								

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

1	G. Selivanova, et al., <i>Nature Medicine</i> ; 3, pp. 632-638, 1997
2	R. K. Brachmann, et al., <i>The EMBO Journal</i> ; 17, pp. 1847-1859, 1998
3	P. V. Nikolova, et al., <i>Proceedings of the National Academy of Science, USA</i> ; 95, pp. 14675-14680, 1998
4	Ted R. Hupp, et al., <i>Cell</i> ; Vol. 83, pp. 237-245, 1995
5	B. A. Foster, et al., <i>Science</i> ; Vol. 286, pp. 2507-2510, 1999
6	Rebecca L. Rawls, <i>Chemical and Engineering News</i> ; pp. 38-41, issue of February 17, 1997
7	Alex N. Bullock, et al., <i>Oncogene</i> ; 19, pp. 1245-1256, 2000
8	Yunje Cho, et al., <i>Science</i> , 265, pp. 346-355, 1994

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)


EXAMINER

DATE CONSIDERED

INFORMATION DISCLOSURE CITATION <i>(Use several sheets if necessary)</i>				ATTY. DOCKET NO. PC10228A				SERIAL NO. 09/443,542					
				APPLICANT Farzan Rastinejad et al.									
				FILING DATE November 19, 1999				GROUP 1614					
<b>U.S. PATENT DOCUMENTS</b>													
EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
													<i>OIA</i>
													<i>JUL 03 2000</i>
													<i>SC144</i>
<b>FOREIGN PATENT DOCUMENTS</b>													
		DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
		WO	94/	1	2	2	0	2	6/9/94	PCT/GB			YES
		WO	97/	3	7	6	4	5	10/16/97	PCT/US			NO
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>													
		Pierre Hainaut et al.; "Redox Modulation of p53 Conformation and Sequence-specific DNA Binding in vitro"; <i>Cancer Research</i> vol. 35, No. 18, pp. 4469-4473, (1993)											
		James J. Ryan et al., "Alteration of p53 Conformation and Induction of Adoptosis in a Murine Erythroleukemia Cell Line By Dimethylsulfoxide"; <i>Leukemia Research</i> , vol. 18, No. 8, pp. 612-621; (1994)											
		C. Randell Brown, et al., "Correcting Temperature-sensitive Protein Folding Defects"; <i>J. Clin. Investigations</i> ; Vol. 99 No. 6, pp 1432-1444, (1997)											
		P.V.M. Shekhar, et al., "Altered P53 conformation: A novel mechanism of wild-type p53 functional inactivation in a model for early human breast cancer"; <i>International Journal of Oncology</i> , vol. 11, No. 5, pp. 1087-1094, (1997)											
		Pierre Hainut, et al., "A Structural Role for Metal Ions in the "Wild-type" Conformatin of the Tumor Suppressor Protein p53"; <i>Cancer Research</i> , vol. 53, no. 8 pp. 1739-1742, (1993)											
		Blagoskonny, et al., "Geldanamycin selectivity destabilizes mutant p53" <i>Proc. Annu. Meet. Am. Assoc. Cancer Res.</i> , vol. 36, page 429, 1995, Abstract 2558											
		Hiroshi Sakagami et al., "Induction of DNA Fragmentation in Human Myelogenous Leukaemic Cell Lines by Phenothiazine-Related Compounds"; <i>Anticancer Research</i> 15 pp.2533-40 (1995)											
		Mark A. Wuonola, et al., "The Primary in Vitro Antitumor Screening of "Half-Mustard Type" Phenothiazines"; <i>Anticancer Research</i> , 17 pp. 3409-3423, (1997)											
		Sylvia Nagy, et al., "Antitumor Activity of Phenothiazine-Related Compounds" <i>Anticancer Research</i> 16, pp. 1915-1918, (1996)											
		Noboru Motohashi, et al., "Synthesis and Antitumor Activity of 1-[2-(Chloroethyl)-3-(2-substituted-10H-phenothiazin-10-yl)alkyl-1-Ureas as Potent Anticancer Agents"; <i>Anticancer Research</i> , vol. 16, pp. 2525-2532 (1996)											
		Marek Gniazdowsky, et al., "Thiol-Dependent Inhibition of RNA Synthesis in vitro By Acridines, Structure-Inhibition Relationships, <i>Cancer Letters</i> , 15, pp. 73-79 (1982)											


RECEIVED

*JUL 06 2000*

INFORMATION DISCLOSURE CITATION <i>(Use several sheets if necessary)</i>		ATTY. DOCKET NO. PC10228A	SERIAL NO. 09/443,542
		APPLICANT Farzan Rastinejad et al.	
		FILING DATE November 19, 1999	GROUP 1614
<i>J</i>		William Wilson, et al., "Hypoxia-Selective Antitumor Agents. 2. Electronic Effects of 4-Substituents on the Mechanisms of Cytotoxicity and Metabolic Stability of Nitracrine Derivatives"; <i>J. Med. Chem.</i> , vol. 32, pp. 31-38 (1989)	
<i>J</i>		T.R. Hupp, "Regulation of p53 Protein Function Through Alterations In Protein-Folding Pathways", <i>Cell. Mol. Life Sci.</i> , vol. 55 pp. 88-95 (1999)	
<i>J</i>		K. Sakagami et al., Chemical Abstracts, vol. 24, No. 25, June 17, 1996, Abstract No. 332043	
<i>J</i>		M. Wuonola et al., Chemical Abstracts, vol. 128, 1998, Abstract No. 175800	
<i>J</i>		M. Wuonola et al., Chemical Abstracts, vol. 128, No. 14, April 6, 1998, Abstract No. 162631	
<i>J</i>		T. Ohnishi, et al., "Restoration of Mutant TP53 to Normal TP53 Function by Glycerol as a Chemical Chaperone", <i>Radiation Research</i> , vol. 151, no. 4 pp. 498-500 (1999)	
EXAMINER		DATE CONSIDERED	<i>6/28/01</i>
<small>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this sheet with next communication to applicant.</small>			

Conforms with FORM PTO-FB-A820

INFORMATION DISCLOSURE



Conforms with FORM PTO-FB-A820

## INFORMATION DISCLOSURE

**EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.